Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors

Stem Cells

Volumn 24, Issue 1, 2006, Pages 105-114

  Drayer, A Lyndsay ^a   Olthof, Sandra G M ^b   Vellenga, Edo ^b  

^a Sanquin Bloedbank Regio Nordoost Groningen   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P70; THROMBOPOIETIN;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SIZE; CELL STIMULATION; CELL SURVIVAL; COLONY FORMATION; HUMAN; HUMAN CELL; MEGAKARYOCYTE; MEGAKARYOPOIESIS; POLYPLOIDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEM CELL; TRANSLATION REGULATION;

ANIMALS; ANTIGENS, CD34; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; MEGAKARYOCYTES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; STEM CELLS; THROMBOPOIETIN;

MAMMALIA;

EID: 33645505599     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2005-0062     Document Type: Article

References (32)

1. de Sauvage FJ, Hass PE, Spencer SD et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mp1 ligand. Nature 1994;369:533-538.
2. Lok S, Kaushansky K, Holly RD et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-568.
3. Wendling F, Maraskovsky E, Debili N et al. cMp1 ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369:571-574.
4. Kaushansky K, Lok S, Holly RD et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mp1 ligand thrombopoietin. Nature 1994;369:568-571.
5. Solar GP, Kerr WG, Zeigler FC et al. Role of c-mp1 in early hematopoiesis. Blood 1998;92:4-10.
6. Sitnicka E, Lin N, Priestley GV et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996;87:4998-5005.
7. Drachman JG, Millett KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem 1999;274:13480-13484.
8. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood 1999;94:1273-1282.
9. Geddis AE, Fox NE, Kaushansky K. Phosphatidylinositol 3-kinase is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mp1-bearing cell lines as well as in primary megakaryocytic progenitors. J Biol Chem 2001;276:34473-34479.
10. Tanaka M, Kirito K, Kashii Y et al. Forkhead family transcription factor FKHRL1 is expressed in human megakaryocytes. Regulation of cell cycling as a downstream molecule of thrombopoietin signaling. J Biol Chem 2001;276:15082-15089.
11. Kirito K, Watanabe T, Sawada K et al. Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J Biol Chem 2002;277:8329-8337.
12. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151-3171.
13. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-1945.
14. Jacinto E, Hall MN. TOR signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 2003;4:117-126.
15. Chen J, Zheng XF, Brown EJ et al. Identification of an 11-Kda Fkbp12-rapamycin-binding domain within the 289-Kda Fkbp12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 1995;92:4947-4951.
16. Choi JW, Chen J, Schreiber SL et al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996;273:239-242.
17. Gingras AC, Raught B, Gygi SP et al. Hierarchical phosphorylation of the translation inhibitor 4E-BPI. Genes Dev 2001;15:2852-2864.
18. Rousseau D, Gingras AC, Pause A et al. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996;13:2415-2420.
19. Dmitriev SE, Terenin IM, Dunaevsky YE et al. Assembly of 48S translation initiation complexes from purified components with mRNAs that have some base pairing within their 5′ untranslated regions. Mol Cell Biol 2003;23:8925-8933.
20. Kwiatkowski DJ. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 2003;67:87-96.
21. Inoki K, Li Y, Xu T et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-1834.
22. Garami A, Zwartkruis FJT, Nobukuni T et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003;11:1457-1466.
23. Avanzi GC, Brizzi MF, Giannotti J et al. M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3. J Cell Physiol 1990;145:458-464.
24. Reinhard C, Thomas G, Kozma SC. A single gene encodes 2 isoforms of the P70 S6 kinase-activation upon mitogenic stimulation. Proc Natl Acad Sci U S A 1992;89:4052-4056.
25. Recher C, Beyne-Rauzy O, Demur C et al. Anti-leukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105:2527-2534.
26. Peralba JM, DeGraffenried L, Friedrichs W et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003;9:2887-2892.
27. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918.
28. Vitrat N, Cohen-Solal K, Pique C et al. Endomitosis of human megakaryocytes are due to abortive mitosis. Blood 1998;91:3711-3723.
29. Kim DH, Sarhassov DD, Ali SM et al. MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-175.
30. Hara K, Maruki Y, Long XM et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002;110:177-189.
31. Sarbassov DD, Ali SM, Kim DH et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-1302.
32. Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-1130.